The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Open accessAbstract
BACKGROUND: Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. METHODS: In this phase 3, randomized, open-label, multicenter study, we assigned 846 patients with chronic-phase Philadelphia chromosome-positive CML in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily). The primary end point was the rate of major molecular response at 12 months. RESULTS: At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P<0.001 for both comparisons). The rates of complete cytogenetic response by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (P<0.001 for both comparisons). Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib twice daily had a significant improvement in the time to progression to the accelerated phase or blast crisis, as compared with those receiving imatinib (P=0.01 and P=0.004, respectively). No patient with progression to the accelerated phase or blast crisis had a major molecular response. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. Discontinuations due to aminotransferase and bilirubin elevations were low in all three study groups. CONCLUSIONS: Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationBaccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Self-citationHochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Self-citationDeininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 616
Self-citationBranford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D.-W., Radich, J. P., Saglio, G., Pane, F., Kamel-Reid, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-150680 · Cited by 388
Self-citationCortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationCortes, J. E., Talpaz, M., O'Brien, S. M., Jones, D. M., Luthra, R., Shan, J., Giles, F. J., Faderl, S. H., Verstovšek, S., Garcia‐Manero, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2139 · Cited by 264
Self-citationNilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Konopleva, M., Ferrajoli, A., Kadia, T., Borthakur, G., Stigliano, D., Shan, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4896 · Cited by 244
Self-citationNilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Rosti, G., Palandri, F., Castagnetti, F., Breccia, M., Levato, L., Gugliotta, G., Capucci, A., Cedrone, M., Fava, C., Intermesoli, T., et al. (2009) · Blood · doi:10.1182/blood-2009-07-232595 · Cited by 210
Self-citationHarmonization of molecular monitoring of CML therapy in Europe
Müller, M. C., Cross, N. C. P., Erben, P., Schenk, T., Hanfstein, B., Ernst, T., Hehlmann, R., Branford, S., Saglio, G., & Hochhaus, A. (2009) · Leukemia · doi:10.1038/leu.2009.168 · Cited by 208
Self-citationBranford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., Goldman, J., & Hughes, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404388 · Cited by 196
Self-citationMüller, M. C., Erben, P., Saglio, G. N., Gottardi, E. M., Nyvold, C. G., Schenk, T., Ernst, T., Lauber, S., Kruth, J., Hehlmann, R., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404983 · Cited by 107
Self-citationDavies, A., Jordanides, N. E., Giannoudis, A., Lucas, C., Hatziieremia, S., Harris, R. J., Jørgensen, H. G., Holyoake, T. L., Pirmohamed, M., Clark, R. E., et al. (2009) · Leukemia · doi:10.1038/leu.2009.166 · Cited by 106
Self-citation15-deoxy-Δ12,14-PGJ2 enhances platelet production from megakaryocytes
O'Brien, J. J., Spinelli, S. L., Tober, J. M., Blumberg, N., Francis, C. W., Taubman, M. B., Palis, J., Seweryniak, K. E., Gertz, J. M., & Phipps, R. P. (2008) · Blood · doi:10.1182/blood-2008-05-158535 · Cited by 101
Cortes, J. E., O'Brien, S. M., Jabbour, E. J., Ferrajoli, A., Borthakur, G. M., Burger, J. A., Wierda, W. G., Garcia‐Manero, G., Thomas, M., Letvak, L. A., et al. (2007) · Blood · doi:10.1182/blood.v110.11.29.29 · Cited by 60
Self-citationBaccarani, M., Druker, B. J., Cortes, J. E., Hughes, T. P., Kim, D., Pane, F., Branford, S., Jin, Y., Krahnke, T., Rudoltz, M. S., et al. (2009) · Blood · doi:10.1182/blood.v114.22.337.337 · Cited by 34
Self-citation
Cited by
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationDissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Metadata
- Authors
- Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R. A., & Kantarjian, H. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-06-17
- Volume
- 362
- Issue
- 24
- Pages
- 2251-2259
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2143939343
- Cited by
- 1,678
- References
- 24
- FWCI
- 105.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.